- Conditions
- Migraine
- Interventions
- Ubrogepant 100 mg, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 518 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 65 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Migraine, With or Without Aura
- Interventions
- Ubrogepant, Placebo-matching Ubrogepant
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,672 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 90
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 77 more
- Conditions
- Headache, Migraine
- Interventions
- Ubrogepant 50 MG [Ubrelvy], Ubrogepant 100 MG [Ubrelvy]
- Drug
- Lead sponsor
- Chicago Headache Center & Research Institute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Naperville, Illinois
- Conditions
- Migraine, With or Without Aura
- Interventions
- Ubrogepant, Placebo-matching Ubrogepant, Usual Care
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 76 Years
- Enrollment
- 1,254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 177
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 137 more
- Conditions
- Migraine
- Interventions
- Ubrogepant, Erenumab, Galcanezumab
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 2
- States / cities
- Springfield, Missouri • West Bend, Wisconsin